NBIX — Neurocrine Biosciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapNeutral

Annual income statement for Neurocrine Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,134	1,489	1,887	2,355	2,861
Cost of Revenue
Gross Profit	1,119	1,466	1,847	2,321	2,808
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	1,031	1,310	1,636	1,785	2,241
Operating Profit	103	179	251	571	619
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	101	214	332	486	705
Provision for Income Taxes
Net Income After Taxes	89.6	155	250	341	479
Net Income Before Extraordinary Items
Net Income	89.6	155	250	341	479
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	89.6	155	250	341	479
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.87	2.09	3.9	3.41	4.84